(Q35706189)

9 August 2017

title

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update (English)

1 reference

Erratum to: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update

9 August 2017

1 reference

1 reference

corrigendum / erratum

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201469%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201469%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Rong-Nan Chien

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201469%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Stephen Locarnini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201469%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Seng-Gee Lim

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201469%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Kwang-Hyub Han

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201469%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Deepak Amarapurkar

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201469%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Graham Cooksley

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201469%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Rosmawati Mohamed

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201469%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Jin-Lin Hou

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201469%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Laurentius A Lesmana

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201469%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Jose D Sollano

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201469%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Dong-Jin Suh

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201469%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Yun-Fan Liaw

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201469%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Masao Omata

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201469%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Teerha Piratvisuth

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201469%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Henry Lik Yuen Chan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201469%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Ed Gane

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201469%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Wasim Jafri

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201469%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

Wan-Long Chuang

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201469%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

language of work or name

1 reference

17 May 2012

1 reference

9 August 2017

published in

Hepatology international

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201469%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201469%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201469%20AND%20SRC:MED&resulttype=core&format=json

14 June 2020

page(s)

531-561

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26201469%20AND%20SRC:MED&resulttype=core&format=json

Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up

14 June 2020

cites work

1 reference

12 December 2020

Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B

1 reference

12 December 2020

Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B

1 reference

12 December 2020

A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China

1 reference

12 December 2020

Side effects of long-term oral antiviral therapy for hepatitis B.

1 reference

12 December 2020

Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.

1 reference

12 December 2020

Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function

1 reference

12 December 2020

Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B.

1 reference

12 December 2020

Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation

1 reference

12 December 2020

Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a

1 reference

12 December 2020

Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study

1 reference

12 December 2020

Hepatitis B virus genotype B is associated with better response to thymosin alpha1 therapy than genotype C.

1 reference

12 December 2020

Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma.

1 reference

12 December 2020

Distinct hepatitis B virus dynamics in the immunotolerant and early immunoclearance phases.

1 reference

12 December 2020

Hepatitis B surface antigen seroclearance during chronic HBV infection

1 reference

12 December 2020

Virologic response to therapy increases health-related quality of life for patients with chronic hepatitis B.

1 reference

12 December 2020

Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management

1 reference

12 December 2020

Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B.

1 reference

12 December 2020

Poor durability of lamivudine effectiveness despite stringent cessation criteria: A prospective clinical study in hepatitis B e antigen‐negative chronic hepatitis B patients

1 reference

12 December 2020

Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China

1 reference

12 December 2020

Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa

1 reference

12 December 2020

Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B.

1 reference

12 December 2020

Liver grafts from anti-hepatitis B core positive donors: a systematic review

1 reference

12 December 2020

Safety and efficacy of two-step peginterferon α-2a treatment in patients of chronic hepatitis B with acute exacerbation

1 reference

12 December 2020

Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study

1 reference

12 December 2020

Long-term outcome in children with chronic hepatitis B: a 24-year observation period

1 reference

12 December 2020

Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group

1 reference

12 December 2020

Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B.

1 reference

12 December 2020

Further Analysis Is Required to Identify an Early Stopping Rule for Peginterferon Therapy That Is Valid for All Hepatitis B e Antigen–Positive Patients *†#

1 reference

12 December 2020

A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.

1 reference

12 December 2020

Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion

1 reference

12 December 2020

Viral Quasi-Species Evolution During Hepatitis Be Antigen Seroconversion

1 reference

12 December 2020

Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus

1 reference

12 December 2020

European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults.

1 reference

12 December 2020

Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters.

1 reference

12 December 2020

Treatment of children with chronic hepatitis B virus infection in the United States: Patient selection and therapeutic options

1 reference

12 December 2020

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

1 reference

12 December 2020

Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection

1 reference

12 December 2020

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update

1 reference

12 December 2020

Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B.

1 reference

12 December 2020

Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report

1 reference

12 December 2020

Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma

1 reference

12 December 2020

Risk of HBV reactivation according to viral status and treatment intensity in patients with hepatocellular carcinoma

1 reference

12 December 2020

Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy.

1 reference

12 December 2020

Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B

1 reference

12 December 2020

Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir

1 reference

12 December 2020

Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

1 reference

12 December 2020

Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus

1 reference

12 December 2020

Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients

1 reference

12 December 2020

Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B.

1 reference

12 December 2020

Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China

1 reference

12 December 2020

Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers.

1 reference

12 December 2020

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

1 reference

12 December 2020

Hepatitis B virus DNA level predicts hepatic decompensation in patients with acute exacerbation of chronic hepatitis B.

1 reference

12 December 2020

Risk Assessment of Hepatitis B Virus–Related Hepatocellular Carcinoma Development Using Liver Stiffness Measurement (FibroScan) σ

1 reference

12 December 2020

Body-mass index and progression of hepatitis B: a population-based cohort study in men.

1 reference

12 December 2020

Determinants for sustained HBeAg response to lamivudine therapy

1 reference

12 December 2020

Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B

1 reference

12 December 2020

Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial

1 reference

12 December 2020

Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis

1 reference

12 December 2020

Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression.

1 reference

12 December 2020

Tailored regimen of interferon alpha for HBeAg-positive chronic hepatitis B: a prospective controlled study

1 reference

12 December 2020

Treatment of HBeAg-negative chronic hepatitis B with pegylated interferon.

1 reference

12 December 2020

Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion

1 reference

12 December 2020

Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.

1 reference

12 December 2020

Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

12 December 2020

Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review

1 reference

12 December 2020

Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia

1 reference

12 December 2020

Hepatitis B immunoglobulin and Lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis

1 reference

12 December 2020

Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation

1 reference

12 December 2020

Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis

1 reference

12 December 2020

High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma

1 reference

12 December 2020

Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis

1 reference

12 December 2020

ALT and viral load decline during PEG-IFN alpha-2b treatment for HBeAg-positive chronic hepatitis B.

1 reference

12 December 2020

The use of transient elastography in the management of chronic hepatitis B.

1 reference

12 December 2020

The clinical implications of hepatitis B virus genotype: Recent advances.

1 reference

12 December 2020

Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma

1 reference

12 December 2020

The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis

1 reference

12 December 2020

Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective.

1 reference

12 December 2020

Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response

1 reference

12 December 2020

Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study.

1 reference

12 December 2020

The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound

1 reference

12 December 2020

Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B.

1 reference

12 December 2020

Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma

1 reference

12 December 2020

Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C.

1 reference

12 December 2020

A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis

1 reference

12 December 2020

Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

1 reference

12 December 2020

Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection

1 reference

12 December 2020

Long-term lamivudine treatment of children with chronic hepatitis B: durability of therapeutic responses and safety

1 reference

12 December 2020

Chronic hepatitis B: update 2009

1 reference

12 December 2020

Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma

1 reference

12 December 2020

Sequential therapy with adefovir dipivoxil and pegylated Interferon Alfa-2a for HBeAg-negative patients

1 reference

12 December 2020

Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men.

1 reference

12 December 2020

Hepatitis B virus infection

1 reference

12 December 2020

Peginterferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B: a randomised study.

1 reference

12 December 2020

Cost-effectiveness analysis of prophylactic lamivudine use in preventing vertical transmission of hepatitis B virus infection.

1 reference

12 December 2020

Polymorphisms Near IL28B and Serologic Response to Peginterferon in HBeAg-Positive Patients With Chronic Hepatitis B

1 reference

12 December 2020

Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues

1 reference

12 December 2020

The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial

1 reference

12 December 2020

Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.

1 reference

12 December 2020

A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization

1 reference

12 December 2020

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

12 December 2020

Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients

1 reference

12 December 2020

Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses

1 reference

12 December 2020

Management of treatment failure in chronic hepatitis B.

1 reference

12 December 2020

Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy

1 reference

12 December 2020

HBV treatment and pregnancy

1 reference

12 December 2020

Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy.

1 reference

12 December 2020

Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load

1 reference

12 December 2020

The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B.

1 reference

12 December 2020

The role of HIV and antiretroviral therapy in bone disease

1 reference

12 December 2020

On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients

1 reference

12 December 2020

Short-term lamivudine therapy in HBeAg-negative chronic active hepatitis B in Taiwan

1 reference

12 December 2020

Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial

1 reference

12 December 2020

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

1 reference

12 December 2020

Hepatitis B virus-related cirrhosis: natural history and treatment

1 reference

12 December 2020

Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis.

1 reference

12 December 2020

2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.

1 reference

12 December 2020

Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F

1 reference

12 December 2020

Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance and Clinical Safety

1 reference

12 December 2020

On-treatment outcome prediction and adjustment during chronic hepatitis B therapy: now and future.

1 reference

12 December 2020

Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B.

1 reference

12 December 2020

Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues

1 reference

12 December 2020

Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients

1 reference

12 December 2020

Reviews for APASL guidelines: immunomodulator therapy of chronic hepatitis B.

1 reference

12 December 2020

Viral hepatitis in solid organ transplantation other than liver.

1 reference

12 December 2020

A randomized, placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B

1 reference

12 December 2020

A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone

1 reference

12 December 2020

Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma

1 reference

12 December 2020

Influence of serum HBV DNA load on recurrence of hepatocellular carcinoma after treatment with percutaneous radiofrequency ablation

1 reference

12 December 2020

Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease.

1 reference

12 December 2020

Four years of lamivudine treatment in Chinese patients with chronic hepatitis B.

1 reference

12 December 2020

Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline

1 reference

12 December 2020

Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death

1 reference

12 December 2020

Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients

1 reference

12 December 2020

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

1 reference

12 December 2020

Decreasing levels of HBsAg predict HBsAg seroclearance in patients with inactive chronic hepatitis B virus infection

1 reference

12 December 2020

Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial

1 reference

12 December 2020

Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy

1 reference

12 December 2020

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

1 reference

12 December 2020

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy

1 reference

12 December 2020

Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients

1 reference

12 December 2020

Current therapy for hepatitis C or D or immunodeficiency virus concurrent infection with chronic hepatitis B.

1 reference

12 December 2020

Antiviral therapy for hepatitis B infection during pregnancy and breastfeeding

1 reference

12 December 2020

Treatment of chronic hepatitis D.

1 reference

12 December 2020

Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men.

1 reference

12 December 2020

Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B

1 reference

12 December 2020

Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open-label study

1 reference

12 December 2020

Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine

1 reference

12 December 2020

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

1 reference

12 December 2020

Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

1 reference

12 December 2020

Predictors of relapse in chronic hepatitis B after discontinuation of anti‐viral therapy

1 reference

12 December 2020

Peginterferon plus adefovir versus either drug alone for hepatitis delta

1 reference

12 December 2020

A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B

1 reference

12 December 2020

Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.

1 reference

12 December 2020

Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study

1 reference

12 December 2020

Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent

1 reference

12 December 2020

Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels

1 reference

12 December 2020

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

1 reference

12 December 2020

Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: A review

1 reference

12 December 2020

Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial

1 reference

12 December 2020

Combination therapy of thymosin alpha-1 and lamivudine for HBeAg positive chronic hepatitis B: A prospective randomized, comparative pilot study

1 reference

12 December 2020

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

1 reference

12 December 2020

Prevalence of and risk factors for hepatitis B viremia after spontaneous hepatitis B surface antigen seroclearance in hepatitis B carriers

1 reference

12 December 2020

Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy

1 reference

12 December 2020

Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice

1 reference

12 December 2020

Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma

1 reference

12 December 2020

Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B

1 reference

12 December 2020

Quantitative Hepatitis B Surface Antigen Levels in Patients With Chronic Hepatitis B After 2 Years of Entecavir Treatment

1 reference

12 December 2020

Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.

1 reference

12 December 2020

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

1 reference

12 December 2020

Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B.

1 reference

12 December 2020

Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase

1 reference

12 December 2020

Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance

1 reference

12 December 2020

Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time

1 reference

12 December 2020

Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score.

1 reference

12 December 2020

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

1 reference

12 December 2020

The clinical significance of persistently normal ALT in chronic hepatitis B infection

1 reference

12 December 2020

A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection

1 reference

12 December 2020

Level of hepatitis B virus DNA in inactive carriers with persistently normal levels of alanine aminotransferase

1 reference

12 December 2020

Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan.

1 reference

12 December 2020

The development of cirrhosis in patients with chronic type B hepatitis: A prospective study

1 reference

12 December 2020

Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B.

1 reference

12 December 2020

Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b

1 reference

12 December 2020

Reactivation of occult hepatitis B virus infection, following treatment of refractory rheumatoid arthritis with abatacept

1 reference

12 December 2020

Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B.

1 reference

12 December 2020

Hepatitis B e antigen and the risk of hepatocellular carcinoma

1 reference

12 December 2020

Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B

1 reference

12 December 2020

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

1 reference

12 December 2020

A randomized, controlled, clinical study of thymosin alpha-1 versus interferon-alpha in [corrected] patients with chronic hepatitis B lacking HBeAg in China [corrected].

1 reference

12 December 2020

Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma

1 reference

12 December 2020

Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia

1 reference

12 December 2020

Long-term outcome of chronic hepatitis B based on histological grade and stage.

1 reference

12 December 2020

Serial HBV DNA levels in patients with persistently normal transaminase over 10 years following spontaneous HBeAg seroconversion

1 reference

12 December 2020